zraR Antibody

What are [89Zr]Zr-labeled antibodies and how are they used in molecular imaging?

[89Zr]Zr-labeled antibodies are radioimmunoconjugates created by attaching the positron-emitting isotope zirconium-89 to monoclonal antibodies via chelator molecules. They function as powerful molecular imaging probes that combine the specificity of antibodies with the sensitivity of positron emission tomography (PET) imaging. The resulting compounds (often called 89Zr-immuno-PET) enable non-invasive visualization of target-expressing tissues with high contrast and resolution .

The most common methodology involves:

• Conjugation of a chelator (typically deferoxamine, DFO) to the antibody

• Purification of the chelator-antibody conjugate

• Radiolabeling with [89Zr]Zr4+ (usually in the form of [89Zr]Zr-oxalate)

• Purification of the final radioimmunoconjugate

These probes are particularly valuable for cancer imaging as they provide information about target expression, allowing for patient stratification and therapeutic monitoring .

What is the typical workflow for developing [89Zr]Zr-labeled antibodies?

The development workflow for [89Zr]Zr-labeled antibodies follows these key steps:

• Antibody selection/production: Identify or develop an antibody with high specificity and affinity for the target

• Chelator conjugation: Conjugate a bifunctional chelator (typically DFO) to the antibody using appropriate chemistry

• Conjugate characterization: Determine the average number of chelators per antibody using methods like radiometric isotopic dilution assay, HPLC-based UV/Vis absorption, or mass spectrometry

• Radiolabeling: Label the conjugate with [89Zr]Zr4+ under optimized conditions

• Quality control: Assess radiochemical purity via iTLC and/or HPLC

• Stability testing: Perform serum stability studies to evaluate the integrity of the radioimmunoconjugate

• Immunoreactivity assessment: Determine if the radioimmunoconjugate maintains binding to its target

• In vivo evaluation: Conduct small animal PET imaging and biodistribution studies

For example, in a recent study developing an anti-TIP1 antibody, researchers achieved 95% purity by SEC-HPLC, confirmed intact mass by native MS, optimized the DFO-to-antibody ratio to 1.05, and achieved 99.9% radiochemical purity with a specific activity of 0.37 MBq/μg .

What are the key parameters for evaluating [89Zr]Zr-labeled antibody quality?

Several critical parameters are used to assess the quality of [89Zr]Zr-labeled antibodies:

• Radiochemical purity: Typically determined by iTLC and/or SEC-HPLC, with >95% considered acceptable

• Specific activity: Expressed in MBq/mg or MBq/nmol, with 2-6 mCi/mg (74-222 MBq/mg) typically considered acceptable for cell-based assays and small animal imaging studies

• Immunoreactive fraction (IRF): Percentage of radiolabeled antibody that maintains target binding, determined by cell-based radioligand binding assays. Values >70% are generally desirable, with >90% being excellent

• Serum stability: Persistence of the radiolabel on the antibody over time in human serum, with >90% stability at 5-7 days being desirable

• Chelator-to-antibody ratio: Typically between 1-3 DFO molecules per antibody for optimal performance

For example, the [89Zr]Zr-DFO-L111 antibody described in result #3 demonstrated an immunoreactive fraction of 96% and maintained >92% stability in human serum over a 7-day period .

How does the degree of chelator conjugation affect [89Zr]Zr-labeled antibody performance?

The chelator-to-antibody ratio is a critical parameter that significantly impacts radioimmunoconjugate performance. Research has shown this relationship is not linear and must be carefully optimized:

• Too few chelators: Results in low radiochemical yields and specific activities

• Too many chelators: Can compromise immunoreactivity and alter pharmacokinetics by changing the antibody's physicochemical properties

Researchers have investigated different DFO-to-antibody ratios by varying molar equivalents of chelator during conjugation (e.g., T5, T10, T20, T60, and T200 to indicate the molar equivalents of DFO used) . Optimal performance is typically achieved with moderate conjugation levels, with studies showing that 3 molar equivalents of DFO leading to a DFO-to-antibody ratio of approximately 1.05 provides an excellent balance .

The impact of chelator conjugation on antibody performance should be evaluated through:

• Surface plasmon resonance (SPR) to measure binding kinetics

• Cell-based immunoreactivity assays

• In vivo biodistribution studies to assess tumor targeting and background uptake

What methodological approaches can optimize the radiolabeling of antibodies with [89Zr]Zr?

Optimizing [89Zr]Zr radiolabeling requires careful consideration of multiple experimental variables:

• Radiolabeling buffer: Affects radiolabeling efficiency and antibody stability

• Reaction volume: Influences reaction kinetics and practical handling

• Temperature: Affects reaction rate but may impact antibody integrity

• Reaction time: Longer times may increase yield but potentially compromise the antibody

• Antibody mass: Smaller quantities require more precise optimization

For consistent results when working with small antibody quantities, researchers should:

• Use high-quality, pure [89Zr]Zr source material

• Carefully neutralize [89Zr]Zr-oxalate solution

• Maintain precise pH control

• Use controlled reaction temperatures

• Include appropriate controls to verify radiolabeling efficiency

How can researchers assess the immunoreactive fraction of [89Zr]Zr-labeled antibodies?

The immunoreactive fraction (IRF) of [89Zr]Zr-labeled antibodies is a critical quality parameter that quantifies the percentage of radioimmunoconjugate that maintains target binding ability. A standardized cell-based assay methodology includes:

• Prepare a dilution of radiolabeled antibody in 1% BSA solution (~10,000 cpm in 50 μl)

• Prepare cell suspension at 5×10^6 cells/ml in PBS

• Add varying volumes of cell suspension to microcentrifuge tubes (500, 400, 300, 250, 200, 150, 50, 0 μl)

• Add 50 μl of radiolabeled antibody to all tubes except background control

• Adjust volumes to 550 μl with PBS

• Incubate for 60 minutes at room temperature with mixing (300 rpm)

• Pellet cells by centrifugation (600g for 2 min)

• Wash pellets three times with ice-cold PBS

• Measure radioactivity in cell pellets using a gamma counter

• Calculate IRF by dividing the antibody-bound radioactivity by the total radioactivity

For orthogonal validation, surface plasmon resonance (SPR) can provide complementary information about binding kinetics (k_on, k_off) and affinity (K_D) . Researchers should aim for IRF values >90% for optimal imaging performance.

What factors influence the in vivo behavior of [89Zr]Zr-labeled antibodies?

The in vivo performance of [89Zr]Zr-labeled antibodies is influenced by multiple factors that researchers must consider:

• Specific activity: Higher specific activities may improve target visualization but can lead to reduced immunoreactive fractions

• Chelator-to-antibody ratio: Affects clearance pattern and non-specific uptake

• Antibody dose: Can influence pharmacokinetics and target saturation

• Radiochemical purity: Impurities like free [89Zr]Zr can accumulate in bone

• Stability of chelator-radiometal complex: Affects background signal and radiation dosimetry

• Antibody glycosylation pattern: Influences clearance and tissue distribution

Recent research with [89Zr]Zr-DFO-L111 demonstrated that preinjection with 4 mg/kg "cold" (unlabeled) antibody before administering [89Zr]Zr-DFO-L111 (7.4 MBq; 20 μg) significantly enhanced tumor-to-muscle SUVmax ratios on day 5 compared to day 2 post-injection (P<0.01) . This highlights the importance of optimizing the administration protocol to improve imaging contrast.

Researchers should systematically evaluate these parameters during radioimmunoconjugate development to achieve optimal target visualization with minimal background uptake.

What methods are available for determining chelator-to-antibody ratios?

Accurate determination of the chelator-to-antibody ratio is essential for radioimmunoconjugate characterization. Several complementary methods can be employed:

• Radiometric isotopic dilution assay:

  • Incubate a known amount of DFO-conjugated antibody with excess radioactive metal

  • Compare to a standard curve of free chelator

  • Calculate the chelator concentration per antibody

• HPLC-based UV/Vis methods:

  • Detect changes in UV absorption profiles

  • Compare with unconjugated antibody standards

  • Calculate modification based on peak differences

• Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-TOF MS/MS):

  • Provides precise molecular weight information

  • Directly measures mass changes upon conjugation

  • Can detect heterogeneity in conjugate populations

Each method has strengths and limitations, and best practice involves using multiple orthogonal approaches to ensure accurate characterization.

How can researchers optimize serum stability testing for [89Zr]Zr-labeled antibodies?

Serum stability is a critical parameter for predicting in vivo performance of [89Zr]Zr-labeled antibodies. A standardized methodology includes:

• Sample preparation:

  • Add radioimmunoconjugate (e.g., 10 μL of 7.4 MBq [~200 μCi]) to human serum (90 μL)

  • Incubate at physiological temperature (37°C) with gentle agitation (300 rpm)

• Sampling timepoints:

  • Collect aliquots at multiple timepoints (e.g., 1, 2, 5, and 7 days)

  • Longer timepoints are needed for antibodies due to their extended circulation half-life

• Analysis methods:

  • Instant thin-layer chromatography (iTLC) with 50 mM DTPA pH 6.0 as mobile phase

  • Radio-HPLC to detect protein-associated radioactivity

  • Conduct all reactions in triplicate for statistical validity

• Data interpretation:

  • Calculate percentage of intact radioimmunoconjugate at each timepoint

  • Plot stability curves using appropriate software (e.g., GraphPad Prism)

  • Compare to established standards (typically >90% stability at 7 days is desirable)

Research has shown that [89Zr]Zr-DFO-L111 maintains >92% stability over 7 days, indicating excellent performance for in vivo applications .

What quality control procedures are essential for [89Zr]Zr-labeled antibodies?

Comprehensive quality control of [89Zr]Zr-labeled antibodies requires multiple analytical methods to ensure safety, efficacy, and reproducibility:

• Radiochemical purity assessment:

  • iTLC with appropriate mobile phase (e.g., 50 mM DTPA pH 6.0)

  • Radio-HPLC using size exclusion columns

  • Acceptance criterion typically >95% radiochemical purity

• Protein integrity verification:

  • Size-exclusion chromatography (SEC-HPLC) to detect aggregation

  • Native mass spectrometry to confirm intact mass and glycosylation pattern

  • SDS-PAGE to assess fragmentation

• Immunoreactivity determination:

  • Cell-based binding assays as detailed in section 2.3

  • Target-specific ELISA methods

  • Surface plasmon resonance for binding kinetics

• Endotoxin testing:

  • LAL (Limulus Amebocyte Lysate) test

  • Essential for preparations intended for in vivo use

• Sterility testing:

  • Required for all preparations for in vivo applications

  • Particularly critical for clinical translation

• Stability assessment:

  • Serum stability studies as described in section 3.2

  • Storage stability at different temperatures

The comprehensive quality control data package is particularly important when preparing for clinical translation or regulatory submissions, as shown in the case of anti-TIP1 antibody L111, where these data served as the basis for the chemistry and manufacturing component of an Investigational New Drug application with the FDA .

What considerations are important when translating [89Zr]Zr-labeled antibodies from preclinical to clinical studies?

Translating [89Zr]Zr-labeled antibodies from preclinical models to clinical applications involves addressing several key considerations:

• Regulatory requirements:

  • Chemistry, Manufacturing, and Controls (CMC) documentation

  • Toxicology studies with the unlabeled antibody-chelator conjugate

  • Dosimetry estimates based on animal biodistribution data

  • Investigational New Drug (IND) application preparation

• Scale-up and reproducibility:

  • Establishing consistent conjugation and radiolabeling procedures

  • Implementing GMP-compliant manufacturing processes

  • Developing validated quality control methods

• Radiation safety:

  • Calculating appropriate patient doses

  • Estimating radiation exposure to critical organs

  • Developing radiation safety protocols for handling and administration

• Clinical protocol design:

  • Determining optimal imaging timepoints (typically 2-5 days post-injection for antibodies)

  • Establishing quantification methods for PET data

  • Planning for potential dose optimization studies

• Antibody humanization considerations:

  • Using fully human antibodies when possible to reduce immunogenicity

  • Monitoring for anti-drug antibody responses in patients

For example, researchers developing the anti-TIP1 antibody L111 specifically designed their study to prepare for first-in-human clinical trials, focusing on determining which cancers would be best suited for therapeutic applications and establishing optimal scheduling for radiation therapy alongside the antibody conjugate .

How does antibody specificity impact [89Zr]Zr-based molecular imaging results?

Antibody specificity is a critical determinant of [89Zr]Zr-immuno-PET imaging quality and data interpretation:

• Target expression profile:

  • Heterogeneous expression within tumors affects signal distribution

  • Expression in normal tissues creates background signal

  • Expression levels influence optimal imaging timepoints

• Cross-reactivity considerations:

  • Off-target binding reduces contrast and complicates interpretation

  • Species-specific differences must be considered when translating from animal models

  • Target homology between preclinical models and humans must be evaluated

• Imaging optimization strategies:

  • Preloading with unlabeled antibody can block non-specific binding sites

  • Dose optimization studies help determine optimal signal-to-noise ratios

  • Timing of imaging post-injection significantly impacts contrast

Research with [89Zr]Zr-DFO-L111 demonstrated that preinjection of unlabeled antibody (4 mg/kg) significantly improved tumor-to-muscle contrast, highlighting how administration protocol optimization can enhance specificity in molecular imaging applications .

What are the critical factors for interpreting quantitative data from [89Zr]Zr-labeled antibody imaging studies?

Accurate interpretation of quantitative data from [89Zr]Zr-immuno-PET requires consideration of multiple technical and biological factors:

• Quantification methods:

  • Standardized uptake values (SUVs) for region-based analysis

  • Tumor-to-background ratios for comparative assessment

  • Dynamic analysis for kinetic parameters when applicable

• Biological considerations:

  • Target expression levels and heterogeneity

  • Vascular permeability and perfusion effects

  • Enhanced permeability and retention (EPR) effect contribution

• Technical variables:

  • Specific activity effects on signal intensity

  • Partial volume effects in small lesions

  • Attenuation correction accuracy

• Temporal factors:

  • Optimal imaging timepoints (typically 2-5 days post-injection)

  • Changes in distribution over time

  • Internalization and metabolism of the radioimmunoconjugate

• Comparative analysis:

  • Comparison with other imaging modalities (CT, MRI)

  • Correlation with biopsy-confirmed target expression

  • Longitudinal changes during treatment

Research has shown that tumor-to-muscle SUVmax ratios for [89Zr]Zr-DFO-L111 significantly improved from day 2 to day 5 post-injection (P<0.01) when using a preloading strategy with unlabeled antibody , demonstrating the importance of temporal factors in data interpretation.

How might next-generation chelators improve [89Zr]Zr-labeled antibody performance?

While DFO is the most commonly used chelator for [89Zr]Zr4+ complexation, research into next-generation chelators aims to address several limitations:

• Improved stability:

  • Developing chelators with higher thermodynamic stability constants

  • Creating structures with enhanced kinetic inertness

  • Reducing in vivo transchelation to endogenous proteins

• Conjugation chemistry innovations:

  • Site-specific conjugation methods to ensure homogeneous products

  • Bioorthogonal approaches for improved control over chelator location

  • Clickable chelators for simplified conjugation procedures

• Multifunctional capabilities:

  • Dual-purpose chelators that can complex both diagnostic and therapeutic radiometals

  • Bifunctional constructs incorporating fluorescent moieties for multimodal imaging

  • Chelators designed for controlled release applications

Emerging chelators such as DFO* (DFO star), DFO-squaramide, and hydroxypyridinone-based systems show promising improvements in [89Zr]Zr4+ retention compared to conventional DFO. These advances may reduce background signal from bone accumulation and improve image contrast in future applications.

What novel applications of [89Zr]Zr-labeled antibodies are emerging in personalized medicine?

[89Zr]Zr-labeled antibodies are finding expanding applications in personalized medicine approaches:

• Treatment selection biomarkers:

  • Non-invasive assessment of target expression before therapy

  • Whole-body mapping of heterogeneous expression patterns

  • Longitudinal monitoring of target dynamics during treatment

• Theranostic approaches:

  • Using imaging data to guide antibody-drug conjugate therapy

  • Predicting response to immune checkpoint inhibitors

  • Combining with therapeutic radionuclides for radioimmunotherapy

• Complex therapeutic monitoring:

  • Assessing changes in the tumor microenvironment during treatment

  • Monitoring immune cell infiltration with specific antibody probes

  • Evaluating resistance mechanisms through target modulation

• Radiation therapy planning:

  • Using [89Zr]Zr-labeled antibodies to identify optimal radiation targets

  • Combining with external beam radiation as in the TIP1-targeting approach

  • Determining optimal scheduling of radiation and immunotherapy

For example, researchers developing the TIP1-targeting antibody L111 specifically designed their first-in-human study to evaluate safety and determine which cancers would be best suited for progression to therapeutic clinical trials, incorporating radiation therapy planning into their approach .